文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

细胞衍生仿生纳米载体用于靶向癌症治疗:细胞膜和细胞外囊泡。

Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.

机构信息

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.

Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

Drug Deliv. 2021 Dec;28(1):1237-1255. doi: 10.1080/10717544.2021.1938757.


DOI:10.1080/10717544.2021.1938757
PMID:34142930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8216268/
Abstract

Nanotechnology provides synthetic carriers for cancer drug delivery that protect cargos from degradation, control drug release and increase local accumulation at tumors. However, these non-natural vehicles display poor tumor targeting and potential toxicity and are eliminated by the immune system. Recently, biomimetic nanocarriers have been widely developed based on the concept of 'mimicking nature.' Among them, cell-derived biomimetic vehicles have become the focus of bionics research because of their multiple natural functions, such as low immunogenicity, long circulation time and targeting ability. Cell membrane-coated carriers and extracellular vesicles are two widely used cell-based biomimetic materials. Here, this review summarizes the latest progress in the application of these two biomimetic carriers in targeted cancer therapy. Their properties and performance are compared, and their future challenges and development prospects are discussed.

摘要

纳米技术为癌症药物输送提供了合成载体,这些载体可以保护货物免受降解,控制药物释放并增加肿瘤部位的局部积累。然而,这些非天然载体显示出较差的肿瘤靶向性和潜在的毒性,并被免疫系统清除。最近,基于“模仿自然”的概念,仿生纳米载体得到了广泛的发展。其中,由于具有多种天然功能,如低免疫原性、长循环时间和靶向能力,细胞衍生的仿生载体已成为仿生研究的焦点。细胞膜包覆的载体和细胞外囊泡是两种广泛使用的基于细胞的仿生材料。本文总结了这两种仿生载体在靶向癌症治疗中的最新应用进展。比较了它们的性质和性能,并讨论了它们未来的挑战和发展前景。

相似文献

[1]
Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles.

Drug Deliv. 2021-12

[2]
Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.

J Nanobiotechnology. 2024-10-6

[3]
Construction of Biomimetic-Responsive Nanocarriers and their Applications in Tumor Targeting.

Anticancer Agents Med Chem. 2022

[4]
Nanomedicines in oral cancer: inspiration comes from extracellular vesicles and biomimetic nanoparticles.

Nanomedicine (Lond). 2022-10

[5]
Unleashing the biomimetic targeting potential of platelet-derived nanocarriers on atherosclerosis.

Colloids Surf B Biointerfaces. 2024-8

[6]
Extracellular Vesicles - Advanced Nanocarriers in Cancer Therapy: Progress and Achievements.

Int J Nanomedicine. 2020-8-26

[7]
Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy.

Drug Discov Today. 2023-4

[8]
Cell-derived membrane biomimetic nanocarriers for targeted therapy of pulmonary disease.

Int J Pharm. 2022-5-25

[9]
Hybrid cell membrane-coated nanoparticles: A multifunctional biomimetic platform for cancer diagnosis and therapy.

Acta Biomater. 2020-8

[10]
Biomimetic nanoarchitecturing: A disguised attack on cancer cells.

J Control Release. 2021-1-10

引用本文的文献

[1]
A New Perspective on Regenerative Medicine: Plant-Derived Extracellular Vesicles.

Biomolecules. 2025-7-28

[2]
Biomimetic cancer cell membrane engineered lipid nanoparticles for enhanced chemotherapy of homologous malignant tumor.

BMC Cancer. 2025-7-1

[3]
Tumor Membrane Based Delivery System Encapsulating Metfornin and TPP1 Peptide for Tumor Immune Therapy.

ACS Biomater Sci Eng. 2025-7-14

[4]
Application of Biomimetic Cell Membrane-Coated Nanocarriers in Cardiovascular Diseases.

Int J Nanomedicine. 2025-6-26

[5]
Advances in constructing biocompatible nanocarriers.

Drug Deliv Transl Res. 2025-6-18

[6]
Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.

Med Oncol. 2025-5-4

[7]
Artificial Cell-Derived Vesicles: Extracellular Vesicle Mimetics for Chondrocyte Restoration in TMJOA Therapy.

Int J Nanomedicine. 2025-4-26

[8]
Rapid synergistic thrombolysis of ischemic stroke guided by high-resolution and high-speed photoacoustic cerebrovascular imaging.

Photoacoustics. 2025-4-4

[9]
Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.

Mater Today Bio. 2025-4-5

[10]
Nanomaterials evoke pyroptosis boosting cancer immunotherapy.

Acta Pharm Sin B. 2025-2

本文引用的文献

[1]
Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.

J Cell Mol Med. 2021-2

[2]
Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response.

Cancer Lett. 2021-3-31

[3]
Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene.

Oncogene. 2021-1

[4]
microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer.

Stem Cell Res Ther. 2020-10-27

[5]
Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells.

PeerJ. 2020-7-20

[6]
Immune (Cell) Derived Exosome Mimetics (IDEM) as a Treatment for Ovarian Cancer.

Front Cell Dev Biol. 2020-9-17

[7]
Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy.

Small. 2020-11

[8]
Leukocyte-Mediated Combined Targeted Chemo and Gene Therapy for Esophageal Cancer.

ACS Appl Mater Interfaces. 2020-10-21

[9]
Cancer Cell-Erythrocyte Hybrid Membrane Coated Gold Nanocages for Near Infrared Light-Activated Photothermal/Radio/Chemotherapy of Breast Cancer.

Int J Nanomedicine. 2020-9-11

[10]
Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.

Cell Death Dis. 2020-9-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索